Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-02

AUTHORS

Carlos Castaneda, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Herbert I. Hurwitz

ABSTRACT

PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. METHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. RESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. CONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study. More... »

PAGES

455-463

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5

DOI

http://dx.doi.org/10.1007/s00280-010-1488-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031662375

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20972873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkyl and Aryl Transferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lamin Type A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mouth Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nuclear Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Precursors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Instituto Nacional de Enfermedades Neopl\u00e1sicas", 
          "id": "https://www.grid.ac/institutes/grid.419177.d", 
          "name": [
            "Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castaneda", 
        "givenName": "Carlos", 
        "id": "sg:person.01030612671.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030612671.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meadows", 
        "givenName": "Kellen L.", 
        "id": "sg:person.014460031617.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014460031617.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Truax", 
        "givenName": "Roxanne", 
        "id": "sg:person.01133626763.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133626763.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morse", 
        "givenName": "Michael A.", 
        "id": "sg:person.013700705377.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, 55905, Rochester, Minnesota, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaufmann", 
        "givenName": "Scott H.", 
        "id": "sg:person.01342126052.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342126052.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "West Virginia University", 
          "id": "https://www.grid.ac/institutes/grid.268154.c", 
          "name": [
            "Mary Babb Randolph Cancer Center, West Virginia University, 26506, Morgantown, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petros", 
        "givenName": "William P.", 
        "id": "sg:person.0610003000.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610003000.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Yali", 
        "id": "sg:person.01357562202.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357562202.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Statkevich", 
        "givenName": "Paul", 
        "id": "sg:person.01254454060.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254454060.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cutler", 
        "givenName": "David L.", 
        "id": "sg:person.0673106361.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673106361.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurwitz", 
        "givenName": "Herbert I.", 
        "id": "sg:person.01242177577.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1073/pnas.0403413101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003416326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2003.12.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004296390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.270.11.6221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004876600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.22.14459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009618696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014070179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.22.14093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015163692"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.5.1404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015234213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017566383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-03-0412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019198461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-419x(97)00011-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022401551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025114095", 
          "https://doi.org/10.1038/sj.onc.1202175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025114095", 
          "https://doi.org/10.1038/sj.onc.1202175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026802485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026802485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.270.43.25827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031151964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(90)90294-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032239893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0536-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033310854", 
          "https://doi.org/10.1007/s00277-008-0536-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-2635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033311674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2005.03.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034672756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.89.14.6403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036302734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.25.15591", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038597429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00379-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046295840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00379-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046295840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.15.10232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051296996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.4243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052654075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.5.1399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052670192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m003469200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052870195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052887834", 
          "https://doi.org/10.1038/sj.onc.1201656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052887834", 
          "https://doi.org/10.1038/sj.onc.1201656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/tx000138v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056296385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/tx000138v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056296385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008313232381", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074623638", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074660237", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.4.1167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074754841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074813249", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074829589", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076575034", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1460-2075.1991.tb04979.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077431375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079010052", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083344559", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-02", 
    "datePublishedReg": "2011-02-01", 
    "description": "PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted.\nMETHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa.\nRESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses.\nCONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-010-1488-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "67"
      }
    ], 
    "name": "Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors", 
    "pagination": "455-463", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "96d56db3293bcbbccd2d2f6ddbdc772c27602438fa7bc47f099432cd8989a5ac"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20972873"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-010-1488-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031662375"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-010-1488-5", 
      "https://app.dimensions.ai/details/publication/pub.1031662375"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-010-1488-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'


 

This table displays all metadata directly associated to this object as RDF triples.

330 TRIPLES      21 PREDICATES      86 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-010-1488-5 schema:about N1f528308a4434c1ab4bf8f2af47a7841
2 N2915f11e23204b59be13b964dfd66127
3 N3d09e2a2c6774702a8db9c47c2c31396
4 N451d74481d5a4383ba1e1b2109f82e01
5 N6271447fe4c24487b7529c24190b0f33
6 N71a379ac3cbe4a56b3415866b9e32773
7 N85ba8a34676d4f6aa023308f6a5128a1
8 N8df857e038f24b69aa44c925c8421386
9 Na156806c8ed84aa7ad5a0bbf88603174
10 Na8974eea2f7e4afeadc055255f558e35
11 Nab8246dbf211423f890accf328957a21
12 Nb7dac27624c448bda86046d4e85f9182
13 Nc40e5e782a48435f82ce406fd7f8771a
14 Nccb96a8a3b7e473fad284378f7dcc7e7
15 Nd2ce6564682a4c3aafd34697865761a9
16 Nd7269d48c4c243cea773de6f33d2b459
17 Ne3d9207632324993b8c1f8aa9a7c2fe8
18 Ne5da5cb3e81d4553aec87b6971d63cc2
19 Nf51b9c9bf6214c858764a81cf895ad9a
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N6825b9ab4bf54be6b414b62c7311f960
23 schema:citation sg:pub.10.1007/s00277-008-0536-2
24 sg:pub.10.1038/sj.onc.1201656
25 sg:pub.10.1038/sj.onc.1202175
26 https://app.dimensions.ai/details/publication/pub.1074623638
27 https://app.dimensions.ai/details/publication/pub.1074660237
28 https://app.dimensions.ai/details/publication/pub.1074813249
29 https://app.dimensions.ai/details/publication/pub.1074829589
30 https://app.dimensions.ai/details/publication/pub.1076575034
31 https://app.dimensions.ai/details/publication/pub.1079010052
32 https://app.dimensions.ai/details/publication/pub.1083344559
33 https://doi.org/10.1002/cncr.21188
34 https://doi.org/10.1002/cncr.22901
35 https://doi.org/10.1002/j.1460-2075.1991.tb04979.x
36 https://doi.org/10.1016/0092-8674(90)90294-o
37 https://doi.org/10.1016/j.ccr.2005.03.024
38 https://doi.org/10.1016/s0304-419x(97)00011-5
39 https://doi.org/10.1016/s0959-8049(02)00379-9
40 https://doi.org/10.1021/tx000138v
41 https://doi.org/10.1023/a:1008313232381
42 https://doi.org/10.1053/j.seminoncol.2003.12.012
43 https://doi.org/10.1073/pnas.0403413101
44 https://doi.org/10.1073/pnas.89.14.6403
45 https://doi.org/10.1074/jbc.270.11.6221
46 https://doi.org/10.1074/jbc.270.43.25827
47 https://doi.org/10.1074/jbc.272.15.10232
48 https://doi.org/10.1074/jbc.272.22.14093
49 https://doi.org/10.1074/jbc.272.22.14459
50 https://doi.org/10.1074/jbc.272.25.15591
51 https://doi.org/10.1074/jbc.m003469200
52 https://doi.org/10.1074/jbc.m503763200
53 https://doi.org/10.1097/coc.0b013e318187dd57
54 https://doi.org/10.1158/0008-5472.can-05-2635
55 https://doi.org/10.1158/1078-0432.ccr-03-0412
56 https://doi.org/10.1158/1078-0432.ccr-06-1262
57 https://doi.org/10.1182/blood.v97.5.1399
58 https://doi.org/10.1182/blood.v97.5.1404
59 https://doi.org/10.1200/jco.2001.19.4.1167
60 https://doi.org/10.1200/jco.2006.09.4243
61 schema:datePublished 2011-02
62 schema:datePublishedReg 2011-02-01
63 schema:description PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. METHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. RESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. CONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.
64 schema:genre research_article
65 schema:inLanguage en
66 schema:isAccessibleForFree false
67 schema:isPartOf N13850d2c558046c78f06fc713fd3a853
68 N214f1bd924354bb7a3bb64d041caa701
69 sg:journal.1088364
70 schema:name Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
71 schema:pagination 455-463
72 schema:productId N1873ad7310f840c3bb0b665cceb761ed
73 N37c196c9853d4a0ebbca6763c3fe3379
74 N5c4574825f7b41e8806ee848d7046a41
75 Nb6340bd21a1745ec818d6cf0face9b7c
76 Ncad5d497234d457f8abc6fb428433fc7
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031662375
78 https://doi.org/10.1007/s00280-010-1488-5
79 schema:sdDatePublished 2019-04-11T00:16
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N66d3330cd66547ed8f03f1496a46cb67
82 schema:url http://link.springer.com/10.1007%2Fs00280-010-1488-5
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N015eb63f57ac4630ab2ff10876246185 rdf:first sg:person.01357562202.28
87 rdf:rest Naa3f6f55f299414c848ba5c63a60c6f9
88 N1334337664f242ff801a70733b89e29f rdf:first sg:person.0673106361.44
89 rdf:rest N1d6106f4a42d4e95a5497b90f601713c
90 N13850d2c558046c78f06fc713fd3a853 schema:volumeNumber 67
91 rdf:type schema:PublicationVolume
92 N1873ad7310f840c3bb0b665cceb761ed schema:name nlm_unique_id
93 schema:value 7806519
94 rdf:type schema:PropertyValue
95 N1d6106f4a42d4e95a5497b90f601713c rdf:first sg:person.01242177577.68
96 rdf:rest rdf:nil
97 N1f528308a4434c1ab4bf8f2af47a7841 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Area Under Curve
99 rdf:type schema:DefinedTerm
100 N214f1bd924354bb7a3bb64d041caa701 schema:issueNumber 2
101 rdf:type schema:PublicationIssue
102 N2915f11e23204b59be13b964dfd66127 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Nuclear Proteins
104 rdf:type schema:DefinedTerm
105 N37c196c9853d4a0ebbca6763c3fe3379 schema:name readcube_id
106 schema:value 96d56db3293bcbbccd2d2f6ddbdc772c27602438fa7bc47f099432cd8989a5ac
107 rdf:type schema:PropertyValue
108 N3a86df4fa3c14a74aa0128d9ca5bb38a rdf:first sg:person.013700705377.06
109 rdf:rest N6e2f28ec432147fa86c1e00a941d6ec3
110 N3d09e2a2c6774702a8db9c47c2c31396 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Humans
112 rdf:type schema:DefinedTerm
113 N451d74481d5a4383ba1e1b2109f82e01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Mouth Mucosa
115 rdf:type schema:DefinedTerm
116 N5c4574825f7b41e8806ee848d7046a41 schema:name dimensions_id
117 schema:value pub.1031662375
118 rdf:type schema:PropertyValue
119 N6271447fe4c24487b7529c24190b0f33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Male
121 rdf:type schema:DefinedTerm
122 N66d3330cd66547ed8f03f1496a46cb67 schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 N6825b9ab4bf54be6b414b62c7311f960 rdf:first sg:person.01030612671.69
125 rdf:rest Nfff091469a034670bdf83afa5c92006d
126 N6e2f28ec432147fa86c1e00a941d6ec3 rdf:first sg:person.01342126052.27
127 rdf:rest Nbc6a69aca35143d28f898a5f3c62c014
128 N71a379ac3cbe4a56b3415866b9e32773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Lamin Type A
130 rdf:type schema:DefinedTerm
131 N85ba8a34676d4f6aa023308f6a5128a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Protein Precursors
133 rdf:type schema:DefinedTerm
134 N8df857e038f24b69aa44c925c8421386 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Treatment Outcome
136 rdf:type schema:DefinedTerm
137 Na156806c8ed84aa7ad5a0bbf88603174 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Piperidines
139 rdf:type schema:DefinedTerm
140 Na8974eea2f7e4afeadc055255f558e35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Neoplasms
142 rdf:type schema:DefinedTerm
143 Naa3f6f55f299414c848ba5c63a60c6f9 rdf:first sg:person.01254454060.82
144 rdf:rest N1334337664f242ff801a70733b89e29f
145 Nab8246dbf211423f890accf328957a21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 Nb6340bd21a1745ec818d6cf0face9b7c schema:name pubmed_id
149 schema:value 20972873
150 rdf:type schema:PropertyValue
151 Nb7dac27624c448bda86046d4e85f9182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adult
153 rdf:type schema:DefinedTerm
154 Nb9fc8af31283483b80f6e1f5f17d2599 rdf:first sg:person.01133626763.37
155 rdf:rest N3a86df4fa3c14a74aa0128d9ca5bb38a
156 Nbc6a69aca35143d28f898a5f3c62c014 rdf:first sg:person.0610003000.44
157 rdf:rest N015eb63f57ac4630ab2ff10876246185
158 Nc40e5e782a48435f82ce406fd7f8771a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Maximum Tolerated Dose
160 rdf:type schema:DefinedTerm
161 Ncad5d497234d457f8abc6fb428433fc7 schema:name doi
162 schema:value 10.1007/s00280-010-1488-5
163 rdf:type schema:PropertyValue
164 Nccb96a8a3b7e473fad284378f7dcc7e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Alkyl and Aryl Transferases
166 rdf:type schema:DefinedTerm
167 Nd2ce6564682a4c3aafd34697865761a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Female
169 rdf:type schema:DefinedTerm
170 Nd7269d48c4c243cea773de6f33d2b459 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Middle Aged
172 rdf:type schema:DefinedTerm
173 Ne3d9207632324993b8c1f8aa9a7c2fe8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Pyridines
175 rdf:type schema:DefinedTerm
176 Ne5da5cb3e81d4553aec87b6971d63cc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Antineoplastic Agents
178 rdf:type schema:DefinedTerm
179 Nf51b9c9bf6214c858764a81cf895ad9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Enzyme Inhibitors
181 rdf:type schema:DefinedTerm
182 Nfff091469a034670bdf83afa5c92006d rdf:first sg:person.014460031617.65
183 rdf:rest Nb9fc8af31283483b80f6e1f5f17d2599
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1088364 schema:issn 0344-5704
191 1432-0843
192 schema:name Cancer Chemotherapy and Pharmacology
193 rdf:type schema:Periodical
194 sg:person.01030612671.69 schema:affiliation https://www.grid.ac/institutes/grid.419177.d
195 schema:familyName Castaneda
196 schema:givenName Carlos
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030612671.69
198 rdf:type schema:Person
199 sg:person.01133626763.37 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
200 schema:familyName Truax
201 schema:givenName Roxanne
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133626763.37
203 rdf:type schema:Person
204 sg:person.01242177577.68 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
205 schema:familyName Hurwitz
206 schema:givenName Herbert I.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68
208 rdf:type schema:Person
209 sg:person.01254454060.82 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
210 schema:familyName Statkevich
211 schema:givenName Paul
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254454060.82
213 rdf:type schema:Person
214 sg:person.01342126052.27 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
215 schema:familyName Kaufmann
216 schema:givenName Scott H.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342126052.27
218 rdf:type schema:Person
219 sg:person.01357562202.28 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
220 schema:familyName Zhu
221 schema:givenName Yali
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357562202.28
223 rdf:type schema:Person
224 sg:person.013700705377.06 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
225 schema:familyName Morse
226 schema:givenName Michael A.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06
228 rdf:type schema:Person
229 sg:person.014460031617.65 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
230 schema:familyName Meadows
231 schema:givenName Kellen L.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014460031617.65
233 rdf:type schema:Person
234 sg:person.0610003000.44 schema:affiliation https://www.grid.ac/institutes/grid.268154.c
235 schema:familyName Petros
236 schema:givenName William P.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610003000.44
238 rdf:type schema:Person
239 sg:person.0673106361.44 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
240 schema:familyName Cutler
241 schema:givenName David L.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673106361.44
243 rdf:type schema:Person
244 sg:pub.10.1007/s00277-008-0536-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033310854
245 https://doi.org/10.1007/s00277-008-0536-2
246 rdf:type schema:CreativeWork
247 sg:pub.10.1038/sj.onc.1201656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052887834
248 https://doi.org/10.1038/sj.onc.1201656
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/sj.onc.1202175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025114095
251 https://doi.org/10.1038/sj.onc.1202175
252 rdf:type schema:CreativeWork
253 https://app.dimensions.ai/details/publication/pub.1074623638 schema:CreativeWork
254 https://app.dimensions.ai/details/publication/pub.1074660237 schema:CreativeWork
255 https://app.dimensions.ai/details/publication/pub.1074813249 schema:CreativeWork
256 https://app.dimensions.ai/details/publication/pub.1074829589 schema:CreativeWork
257 https://app.dimensions.ai/details/publication/pub.1076575034 schema:CreativeWork
258 https://app.dimensions.ai/details/publication/pub.1079010052 schema:CreativeWork
259 https://app.dimensions.ai/details/publication/pub.1083344559 schema:CreativeWork
260 https://doi.org/10.1002/cncr.21188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026802485
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1002/cncr.22901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017566383
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1002/j.1460-2075.1991.tb04979.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1077431375
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/0092-8674(90)90294-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1032239893
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/j.ccr.2005.03.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034672756
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s0304-419x(97)00011-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022401551
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s0959-8049(02)00379-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046295840
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1021/tx000138v schema:sameAs https://app.dimensions.ai/details/publication/pub.1056296385
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1023/a:1008313232381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303084
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1053/j.seminoncol.2003.12.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004296390
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1073/pnas.0403413101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003416326
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1073/pnas.89.14.6403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036302734
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1074/jbc.270.11.6221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004876600
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1074/jbc.270.43.25827 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031151964
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1074/jbc.272.15.10232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051296996
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1074/jbc.272.22.14093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015163692
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1074/jbc.272.22.14459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009618696
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1074/jbc.272.25.15591 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038597429
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1074/jbc.m003469200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052870195
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1074/jbc.m503763200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005457814
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1097/coc.0b013e318187dd57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045077743
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1158/0008-5472.can-05-2635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033311674
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1158/1078-0432.ccr-03-0412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019198461
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1158/1078-0432.ccr-06-1262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014070179
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1182/blood.v97.5.1399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052670192
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1182/blood.v97.5.1404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015234213
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1200/jco.2001.19.4.1167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074754841
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1200/jco.2006.09.4243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052654075
315 rdf:type schema:CreativeWork
316 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
317 schema:name Duke University Medical Center, 27710, Durham, North Carolina, USA
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.268154.c schema:alternateName West Virginia University
320 schema:name Mary Babb Randolph Cancer Center, West Virginia University, 26506, Morgantown, WV, USA
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
323 schema:name Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA
324 rdf:type schema:Organization
325 https://www.grid.ac/institutes/grid.419177.d schema:alternateName Instituto Nacional de Enfermedades Neoplásicas
326 schema:name Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
327 rdf:type schema:Organization
328 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
329 schema:name Mayo Clinic, 55905, Rochester, Minnesota, USA
330 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...